Prostaglandin E receptor subtype EP4 agonist serves better to protect cochlea than prostaglandin E1.

Author(s)
Hori, Ryusuke; Nakagawa, Takayuki; Yamamoto, Norio; Hamaguchi, Kiyomi; Ito, Juichi

Citation
Auris nasus larynx (2013), 40(6): 539-542

Issue Date
2013-12

URL
http://hdl.handle.net/2433/178677

© 2013 Published by Elsevier Ireland Ltd.; この論文は出版社版でありません。引用の際には出版社版をご確認ご利用ください。This is not the published version. Please cite only the published version.
Prostaglandin E Receptor Subtype EP4 Agonist Serves Better to Protect Cochlea than Prostaglandin E1

RYUSUKE HORI1,2, TAKAYUKI NAKAGAWA1, NORIO YAMAMOTO1, KIYOMI HAMAGUCHI1,2 & JUICHI ITO1

1 Department of Otolaryngology, Head and Neck Surgery, Graduate School of Medicine, Kyoto University, Kyoto and 2 Department of Otolaryngology, Tenri Hospital, Tenri, Japan

Corresponding to Dr. Takayuki Nakagawa,

Department of Otolaryngology-Head and Neck Surgery, Graduate School of Medicine, Kyoto University, Kawaharacho 54, Shogoin, Sakyo-ku, 606-8507 Kyoto, Japan.

E-mail: tnakagawa@ent.kuhp.kyoto-u.ac.jp

Tel: +81-75-751-3346 Fax: +81-75-751-7225
Introduction

Prostaglandin E1 (PGE1) has long been clinically used as a vasodilator, and has been proven to be effective for diverse circulatory disorders. Disorders associated with cochlear blood flow have been considered some of the principle causes of sudden sensorineural hearing loss (SSHL) [1], providing the rationale for the clinical use of several vasodilators, including PGE1, for treatment of SSHL. Although PGE1 is a therapeutic option for SSHL, its clinical benefit remains controversial [2-4]. PGE1 binds primarily to E-prostanoid receptors (EP) 1–4 [5], resulting in a variety of biological effects, including vasodilation. In the central nervous system, some EP signaling pathways mediate neurotoxic effects, but others, paradoxically, appear to mediate protective effects [6]. Therefore, activation or inhibition of specific EPs might have superior therapeutic potential than does PGE1 [6-8].

Previous studies have focused on the roles of EP4 in the cochlea and on cochlear protection by pharmacological activation of EP4. EP4-deficient mice show slight hearing loss and are susceptible to noise-induced hearing loss [9]. Local application of an EP4 agonist has been shown to significantly attenuate noise-induced hearing loss in mice [9] and guinea pigs [10]. These findings strongly suggest the superior potential of EP4 agonists, compared with PGE1, for cochlear protection in clinic. However,
comparative assessments of the efficacy of local application of EP4 agonists and PGE1, which are crucial to precede clinical trials, have not been performed in cochlear protection investigations. Therefore, this investigation aimed to examine whether an EP4 agonist offered superior protective effects on cochleae, as compared with PGE1, against noise trauma. For this investigation, a guinea pig model of noise-induced hearing loss was used to compare the protective effects of ONO-AE1-437, an EP4 agonist, with those afforded by PGE1, following local application.

Material and methods

Experimental animals

Hartley guinea pigs, weighing 350–400g, were purchased from Japan SLC (Hamamatsu, Japan). The Animal Research Committee of the Graduate School of Medicine, Kyoto University, Japan, approved all of the experimental protocols. Animal care was supervised by the Institute of Laboratory Animals of the Graduate School of Medicine, Kyoto University. All experimental procedures involving animals were performed in accordance with the National Institutes of Health’s (USA) Guide for the Care and Use of Laboratory Animals.
Drug application

The EP4 agonist, ONO-AE1-437, and PGE1, alprostadil (both from Ono Pharmaceutical, Osaka, Japan) were applied to the round window of guinea pig cochleae (n = 6 for ONO-AE1-437, n = 5 for PGE1), as described previously [10]. In our previous studies, ONO-AE1-329, a no-water soluble EP4 agonist was dissolved in dimethyl sulfoxide followed by dilution in physiological saline, and locally administered. As alprostadil is a water-soluble agent, a water-soluble EP4 agonist, ONO-AE1-437 was chosen for the present study. Both agents were dissolved in physiological saline to a final concentration of 1 mg/mL. Under general anesthesia with midazolam (10 mg/kg; intramuscular) and xylazine (10 mg/kg; intramuscular), the left otic bulla of experimental animals was opened to expose the round window membrane. A piece of gelatin, previously immersed in a solution of either the EP4 agonist or PGE1, was placed on the round window membrane of each animal. For the animals in the control group, a piece of gelatin immersed in physiological saline was applied (n = 5).

Noise exposure and auditory brainstem response (ABR) recording

Immediately after drug application, animals were exposed to 4-kHz octave band noise at 120-dB sound pressure level (SPL) for 5 hours in a ventilated-sound exposure chamber.
fitted with speakers driven by a noise generator and a power amplifier. A 1/2-inch condenser microphone and a fast Fourier transform analyzer (both from Sony, Tokyo, Japan) were used to monitor and calibrate sound levels at multiple locations within the chamber to ensure uniformity of the stimulus. The stimulus intensity varied by a maximum of 3-dB SPL across the measured sites within the exposure chamber. ABRs were recorded at frequencies of 4, 8, and 16 kHz before noise exposure, and on Days 3, 7, 14, and 21 after exposure. The thresholds of the ABRs at each frequency were determined, as described previously [10]. To test effects of local drug application on hearing, ABR recording was performed in normal guinea pigs (n = 4) following placement of a piece of gelatin immersed in physiological saline on the round window membrane.

**Histological assessment**

At the conclusion of the experiment (post-exposure Day 21), each cochlea was subjected to histological analysis. Three regions of the cochlear sensory epithelia, at a distances of 30–50% (second turn), 50–70% (mid-basal portion), and 70–90% (basal portion) from the apex [11], were used for quantitative assessments of hair cell loss. Immunohistochemical staining for myosin VIa and F-actin labeling by phalloidin was
conducted to label the inner hair cells (IHCs) and the outer hair cells (OHCs).

Anti-myosin VIIa rabbit polyclonal antibody (dilution, 1:500; Proteus BioSciences, Ramona, CA, USA) was used as the primary antibody, and Alexa 568-conjugated goat anti-rabbit immunoglobulin G (dilution, 1:500) was used as the secondary antibody. After immunostaining for myosin VIIa, the specimens were stained with fluorescein-phalloidin (1:400; Molecular Probes, Eugene, OR, USA) and examined by confocal microscopy (TCS SP2; Leica Microsystems, Wetzlar, Germany). Nonspecific labeling was tested by omitting the primary antibody from the staining procedures. The numbers of IHCs and OHCs in 0.2-mm-long regions of the apical, middle, and basal portions of the cochleae were independently counted by 3 investigators; the average of the 3 counts was used in subsequent analyses.

Statistical analysis

The overall effects of applied drugs on ABR threshold shifts were examined using two-way factorial analysis of variance with the post-hoc Fisher protected least significant difference test (Fisher’s PLSD). Differences in the numbers of IHCs and OHCs in each region of cochleae were compared between experimental groups using one-way factorial analysis of variance with Fisher’s PLSD. *P* values <0.05 were
considered statistically significant. Values were expressed as the mean and the standard
deviation (SD).

Results

ABR threshold shifts

The time course of the ABR threshold shifts in noise-exposed animals at 4, 8, and 16
kHz are shown in Fig. 1. The overall effects of applied drugs were significant at 4, 8, or
16 kHz respectively (p < 0.0001). The differences in the threshold shifts between the
EP4 agonist- and PGE1-treated cochleae were shown to be significant at 4, 8 or 16 kHz
(p < 0.0001), and those between the EP4 agonist- and saline-treated cochleae were
significant at 4, 8 or 16 kHz (p < 0.0001 for 4 or 16 kHz, p = 0.0004 for 8 kHz). No
significant differences in the threshold shifts were found between the PGE1- and
saline-treated cochleae at each frequency (p = 0.73, 0.06, 0.36 for 4, 8, 16 kHz). No
significant elevation of ABR thresholds was found in normal guinea pigs after local
application of gelatin immersed in saline.

Histological assessment

Immunostaining for myosin VIIa and phalloidin staining for F-actin demonstrated
severe degeneration of the OHCs in the second turn, mid-basal, and basal portions of
the PGE1-treated cochleae (Fig. 2A, C, E). By contrast, OHC degeneration was limited
in the EP4 agonist-treated cochleae (Fig. 2B, D, F). The IHCs were preserved in both
experimental groups (Fig. 2A-F). Quantitative assessments revealed significant
differences in the numbers of surviving OHCs among three groups in each portion (Fig.
3A; p = 0.013, 0.028, 0.038 for the second, mid-basal, basal portion). In the second
portion, significant differences in the numbers of surviving OHCs were found between
the PGE1- and saline-treated cochleae (p = 0.039) and between the EP4 agonist- and
saline-treated cochleae (p = 0.04). In the mid-basal and basal portion, the numbers of
surviving OHCs in the EP4-treated cochleae were significantly higher than those in the
PGE1- or saline-treated cochleae (Fig. 3A; p = 0.026 or 0.012 for EP4 v.s. PGE1 or
saline in the mid-basal, p = 0.021 or 0.028 for EP4 v.s. PGE1 or saline in the basal). No
significant differences were observed in the numbers of surviving IHCs among three
groups (Fig. 3B).

Discussion

The expression of four EP subtypes in the cochlea have been demonstrated [9, 10,
12-14], suggesting physiological or pathophysiological roles of EPs in the auditory
function [8]. Previous studies have indicated the involvement of EP4 in the physiopathology of cochleae and the therapeutic capability of EP4 agonists for noise-induced hearing loss [9, 10], suggesting the potential of EP4 agonists as therapeutic agents for acute sensorineural hearing loss. As PGE1 has also often been used as a therapeutic option for SSHL, the ultimate goal of this experiment was to provide preclinical evidence regarding an improved beneficial therapeutic option. Before conducting a clinical trial to examine the efficacy of EP4 agonists for the treatment of SSHL, demonstration of the differential efficacy of EP4 agonists and PGE1 in an animal model of acute sensorineural hearing loss was desirable. The present results clearly demonstrated that the protective effects of an EP4 agonist on the cochleae were superior to those of PGE1, both functionally and histologically, suggesting that specific activation of EP4 can boost the therapeutic potential of PGE1 for SSHL. Previously, we examined effects of the lipophilic EP4 agonist, ONO-AE1-329 on noise-induced hearing loss in a guinea pig model and demonstrated significant protection of cochleae in both pre- and post-traumatic treatment. The hearing gain following post-traumatic treatment was significant, but not as obvious as seen in pre-traumatic treatment. To clarify the difference in protective effects between a specific EP4 agonist and PGE1, pre-traumatic treatment was employed in the present study. In
the current study, a water soluble EP4 agonist, ONO-AE1-437 was investigated. Considering its potential clinical application, the water-soluble nature may be beneficial.

Both EP2 and EP4 induce intracellular production of cyclic adenosine monophosphate (cAMP), while activation of EP3 results in decreased cAMP concentrations [6-8]. Therefore, EP2 agonists or EP3 antagonists might have similar effects on noise-induced hearing loss, as did the EP4 agonist in this study, and this should be investigated in future studies. In addition, it is also necessary to examine the effects of EP4 agonists in other models of acute sensorineural hearing loss. Prior to clinical application of local EP4 agonists for treatment of acute sensorineural hearing loss, determination of the therapeutic treatment window will also need to be estimated.

In conclusion, the current study showed that local EP4 agonist treatment was superior to local PGE1 treatment for the protection of auditory function and hair cells against noise-induced damage in guinea pigs. Additional research will be required to translate the findings of this study into recommendations for regular clinical application of EP4 agonists for the treatment of SSHL.

Acknowledgement
This study was supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan, a Grant-in-Aid for Research on Sensory and Communicative Disorders from the Japanese Ministry of Health, Labour and Welfare and a collaborative research grant to Kyoto University from Ono Pharmaceutical. We thank Ono Pharmaceutical Co., Ltd. for providing ONO-AE1-437 and PGE1.

**Conflict of interest:** The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.
References


Figure legends

Fig. 1: Alterations in threshold shifts of the auditory brain-stem responses (ABRs) in treated cochleae at frequencies of 4 (A), 8 (B), and 16 kHz (C). The overall effects of applied drugs were significant at 4, 8 or 16 kHz ($p < 0.0001$). The differences in ABR threshold shifts at 4, 8, and 16 kHz between the E-prostanoid receptor 4 (EP4) agonist- and prostaglandin E1 (PGE1)- or saline-treated cochleae were significant (*). Bars represent the SD.

![Graph of ABR threshold shifts at 4 kHz, 8 kHz, and 16 kHz](image)

Fig. 2: Immunostaining for myosin VIIa (myo, red) and F-actin labeling with phalloidin (pha, green) of cochlear sensory epithelia in the second turn, mid-basal, and basal portions. Severe loss of outer hair cells (OHC) was observed in the prostaglandin E1-treated cochlea (A, C, E). Degeneration of OHCs was limited in the specimen treated with an E-prostanoid 4 receptor agonist (B, D, F). No significant difference in inner hair cells (IHC) was observed between the 2 treatments. Bars represent 25 µm.
Fig. 3: Numbers of surviving outer (OHC, A) and inner hair cells (IHC, B) in the second, mid-basal, and basal portions of treated cochleae. Asterisks indicate statistical significance. Bars represent the SD.